Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Prediction of new disease indications for approved drugs by computational methods has been based largely on the genomics signatures of drugs and diseases. We propose a method for drug repositioning that uses the clinical signatures extracted from over 13 years of electronic medical records from a tertiary hospital, including >9.4 M laboratory tests from >530,000 patients, in addition to diverse genomics signatures. Cross-validation using over 17,000 known drug–disease associations shows this approach outperforms various predictive models based on genomics signatures and a well-known “guilt-by-association” method. Interestingly, the prediction suggests that terbutaline sulfate, which is widely used for asthma, is a promising candidate for amyotrophic lateral sclerosis for which there are few therapeutic options. In vivo tests using zebrafish models found that terbutaline sulfate prevents defects in axons and neuromuscular junction degeneration in a dose-dependent manner. A therapeutic potential of terbutaline sulfate was also observed when axonal and neuromuscular junction degeneration have already occurred in zebrafish model. Cotreatment with a β 2-adrenergic receptor antagonist, butoxamine, suggests that the effect of terbutaline is mediated by activation of β 2-adrenergic receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Drug target identification using side-effect similarity
Campillos, M., Kuhn, M., Gavin, A.-C., Jensen, L. J., & Bork, P. (2008) · Science · doi:10.1126/science.1158140 · Cited by 1,248 · cited 1×
“In equation (5), the higher score is mainly derived by the larger Pc, and minimum difference between Pg and Pc (Pc – Pg).”
Background
Cited by
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Drug repurposing from the perspective of pharmaceutical companies
Cha, Y., Erez, T., Reynolds, I. J., Kumar, D., Ross, J., Koytiger, G., Kusko, R., Zeskind, B., Risso, S., Kagan, E., et al. (2018) · British Journal of Pharmacology · doi:10.1111/bph.13798 · Cited by 429
Axes of a revolution: challenges and promises of big data in healthcare
Shilo, S., Rossman, H., & Segal, E. (2020) · Nature Medicine · doi:10.1038/s41591-019-0727-5 · Cited by 370
Leveraging big data to transform target selection and drug discovery
Chen, B., & Butte, A. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.318 · Cited by 160
“47 extracted clinical features from over 13 years of EMRs, including > 9.4 M laboratory tests of > 530,000 patients, in addition to diverse genomics features.”
BackgroundInfluentialSelf-citationNetwork medicine framework for identifying drug-repurposing opportunities for COVID-19
Morselli Gysi, D., do Valle, Í., Zitnik, M., Ameli, A., Gan, X., Varol, O., Ghiassian, S. D., Patten, J. J., Davey, R. A., Loscalzo, J., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025581118 · Cited by 107
“Drug-repurposing algorithms rank drugs based on one or multiple streams of information, such as molecular profiles (2), chemical structures (3), adverse profiles (4), molecular docking (5), electronic health records (6), pathway analysis (7), genome wide association studies (7), and network perturbations (7–15).”
Background
Metadata
- Authors
- Paik, H., Chung, A.-Y., Park, H.-C., Park, R. W., Suk, K., Kim, J., Kim, H., Lee, K., & Butte, A. J.
- Venue
- Scientific Reports
- Published
- 2015-03-05
- Volume
- 5
- Issue
- 1
- Pages
- 8580-8580
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2036906022
- Cited by
- 59
- References
- 2
- FWCI
- 5.32
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records. https://app.cochat.ai/papers/10.1038/srep08580
- The paper
- Paik, H., Chung, A.-Y., Park, H.-C., Park, R. W., Suk, K., Kim, J., Kim, H., Lee, K., & Butte, A. J. (2015). Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records. Scientific Reports. https://doi.org/10.1038/srep08580
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.